Mortality Lower With Lung Volume Reduction Surgery in Emphysema
By Elana Gotkine HealthDay Reporter
TUESDAY, Jan. 28, 2025 -- For patients with advanced emphysema, endobronchial valve placement (EBV) is associated with higher mortality and morbidity compared with lung volume reduction surgery (LVRS), according to a study presented at the annual meeting of The Society of Thoracic Surgeons, held from Jan. 24 to 26 in Los Angeles.
J.W. Awori Hayanga, M.D., M.P.H., from West Virginia University in Morgantown, and colleagues examined data from the U.S. Centers for Medicare and Medicaid Services inpatient claims database for all beneficiaries with severe emphysema undergoing either LVRS or EBV between Jan. 1, 2019, and Dec. 31, 2022, to compare outcomes.
Overall, 3,219 patients underwent lung volume reduction therapy: LVRS in 2,378 and EBV in 841. The researchers found that compared with those who underwent LVRS, EBV patients had lower Elixhauser comorbidity scores, shorter length of stay, and lower hospital charges prior to risk adjustment. Most of the LVRS procedures were minimally invasive (1,897 video-assisted thoracoscopic/robotic surgeries versus 481 open surgeries). EBV was associated with higher 30-day mortality, 30-day readmission rate, reintervention rate, and 30-day readmission with pneumothorax, higher supplementary oxygen requirement, and higher all-cause mortality at one year compared with LVRS after doubly robust risk adjustment including frailty (adjusted odds ratios, 2.68, 1.4, 17.2, 2.09, 3.49, and 1.75, respectively).
"Patients undergoing EBV placement have higher occurrences of various complications over time, often need a greater number of interventions, and even suffer higher mortality compared to those undergoing LVRS in contemporary surgical practice, where techniques have become much less invasive than they were 20 years ago when surgical options were first evaluated," Hayanga said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
THURSDAY, June 5, 2025 -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel...
Cardiorespiratory Effects of Smoke Fine Particulate Matter From Wildfires Can Persist for Months
THURSDAY, June 5, 2025 -- The cardiorespiratory effects of smoke fine particulate matter (PM2.5), a primary wildfire emission that can spike for months after a wildfire begins...
Endolymphatic Sac Decompression Effective for Vertigo, Migraine
WEDNESDAY, May 28, 2025 -- For Meniere disease (MD) patients with migraine, endolymphatic sac decompression (ELSD) is effective, providing postoperative relief of vertigo and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.